Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan

PHASE2CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

February 20, 2015

Primary Completion Date

February 9, 2017

Study Completion Date

July 21, 2021

Conditions
Multiple Myeloma
Interventions
DRUG

Lenalidomide

DRUG

Dexamethasone

BIOLOGICAL

Elotuzumab (BMS-901608)

Trial Locations (28)

1138677

Local Institution, Bunkyo-ku

1358550

Local Institution, Koto-ku

1508935

Local Institution, Shibuya-ku

1608582

Local Institution, Shinjuku-Ku

1628655

Local Institution, Shinjuku-ku

1900014

Local Institution, Tachikawa-shi

2608677

Local Institution, Chiba

2968602

Local Institution, Kamogawa-shi

3091793

Local Institution, Kasama-shi

3200834

Local Institution, Utsunomiya

3508550

Local Institution, Kawagoe-shi

3718511

Local Institution, Maebashi

3770280

Local Institution, Shibukawa-shi

4313192

Local Institution, Hamamatsu

4600001

Local Institution, Nagoya

4678602

Local Institution, Nagoya

5300012

Local Institution, Osaka

5438555

Local Institution, Osaka

6028566

Local Institution, Kyoto

7011192

Local Institution, Okayama

7200001

Local Institution, Fukuyama-shi

7900024

Local Institution, Matsuyama

8128582

Local Institution, Fukuoka

8920853

Local Institution, Kagoshima

9518566

Local Institution, Niigata

9808574

Local Institution, Sendai

0308553

Local Institution, Aomori

0208505

Local Institution, Morioka

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AbbVie

INDUSTRY

lead

Bristol-Myers Squibb

INDUSTRY